Geode Capital Management’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-15,630
| Closed | -$78.4K | – | 4603 |
|
|
2024
Q3 | $78.4K | Sell |
15,630
-3,173
| -17% | -$20.6K | ﹤0.01% | 4165 |
|
|
2024
Q2 | $124K | Sell |
18,803
-1,122
| -6% | -$7.63K | ﹤0.01% | 4073 |
|
|
2024
Q1 | $219K | Buy |
19,925
+10,621
| +114% | +$115K | ﹤0.01% | 3911 |
|
|
2023
Q4 | $126K | Buy |
9,304
+397
| +4% | +$6.43K | ﹤0.01% | 4106 |
|
|
2023
Q3 | $193K | Buy |
8,907
+826
| +10% | +$26.5K | ﹤0.01% | 3998 |
|
|
2023
Q2 | $311K | Buy |
8,081
+3,672
| +83% | +$130K | ﹤0.01% | 3839 |
|
|
2023
Q1 | $122K | Sell |
4,409
-1
| -0% | -$34 | ﹤0.01% | 4266 |
|
|
2022
Q4 | $167K | Sell |
4,410
-269
| -6% | -$19.6K | ﹤0.01% | 4197 |
|
|
2022
Q3 | $567K | Buy |
4,679
+11
| +0.2% | +$1.98K | ﹤0.01% | 3658 |
|
|
2022
Q2 | $816K | Buy |
4,668
+54
| +1% | +$11.4K | ﹤0.01% | 3514 |
|
|
2022
Q1 | $1.34M | Buy |
4,614
+238
| +5% | +$90.3K | ﹤0.01% | 3475 |
|
|
2021
Q4 | $2.29M | Buy |
4,376
+3,103
| +244% | +$2.23M | ﹤0.01% | 3302 |
|
|
2021
Q3 | $483K | Buy |
1,273
+490
| +63% | +$210K | ﹤0.01% | 4046 |
|
|
2021
Q2 | $698K | Sell |
783
-461
| -37% | -$353K | ﹤0.01% | 3780 |
|
|
2021
Q1 | $1.48M | Buy |
1,244
+644
| +107% | +$888K | ﹤0.01% | 3398 |
|
|
2020
Q4 | $796K | Buy |
600
+375
| +167% | +$550K | ﹤0.01% | 3436 |
|
|
2020
Q3 | $507K | Buy |
225
+106
| +89% | +$240K | ﹤0.01% | 3426 |
|
|
2020
Q2 | $268K | Buy |
+119
| New | +$324K | ﹤0.01% | 3581 |
|
Geode Capital Management's BIOR Position: Q4 2024 in Review
Geode Capital Management sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2024, closing a stake of 15,630 shares — an estimated $78.4K sold.
Geode Capital Management first reported a position in BIOR in Q2 2020 and held it in 18 quarters. The position peaked at $2.29M in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOR as of Q4 2024.
- Geode Capital Management reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Geode Capital Management sold 15,630 Biora Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $78.4K.
- Geode Capital Management first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2020 and held it in 18 quarters.
- Geode Capital Management's Biora Therapeutics, Inc. Common Stock position peaked at $2.29M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2024.
Based on Geode Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.